NAD+

The non-peptide square

NAD+ stands for nicotinamide adenine dinucleotide. It is a coenzyme: a small helper molecule that enzymes use during chemical reactions. Enzymes are proteins that make those reactions possible at useful speeds. NAD+ is not a chain of amino acids, so it is not a peptide.

Cells use NAD+ in reactions involving energy and in processes that consume it, including aspects of DNA repair. DNA is the genetic material inside cells. NAD+ and NADH are chemically related forms involved in transferring electrons, small charged particles, during these reactions.

The cell-biology review describes this busy set of roles. Knowing that a substance is necessary inside a cell does not tell us what an external preparation will do. Location, chemical form, and the way a study supplies the material all matter.

The precursor distinction

A precursor is a molecule the body can use to make another molecule. Nicotinamide riboside, usually shortened to NR, and nicotinamide mononucleotide, or NMN, are studied as NAD+ precursors. They are not alternative names for NAD+.

For example, an NMN trial in women after menopause with prediabetes examined metabolic measurements. Prediabetes means blood sugar above the usual range but below the diabetes threshold. The study concerned NMN rather than direct NAD+. It cannot establish what an NAD+ research product does, and its findings cannot be stretched to everyone.

The 2025 review of human precursor studies describes inconsistent translation from blood-level changes to meaningful clinical outcomes. The review also notes limited human evidence about tissue-specific NAD+ changes with aging. A tidy aging story is broader than the available human measurements.

Direct NAD+ has its own small record

An exploratory human NAD+ study measured blood and urine chemistry during an intravenous infusion, meaning material delivered into a vein. It was a pilot: an early, limited investigation designed to examine a narrower question. It did not establish a lasting wellness or aging benefit.

Tracking metabolites, the substances produced as a molecule is processed, helps describe chemistry. It does not by itself establish better memory, more energy, or longer life. Those questions need relevant outcomes and suitable comparison groups.

Tolerability is a research question too

A retrospective tolerability pilot, which looked back at existing records rather than assigning a controlled experiment, described gastrointestinal symptoms, faster heart rate, and chest pressure during direct-NAD+ infusions. That design cannot establish a complete risk profile or reliable event rates.

Direct NAD+ is not an FDA-approved drug. Compounded preparations are not FDA-approved either. A small clinical report cannot establish long-term safety, and a naturally occurring coenzyme is not automatically safe in every preparation or setting.

The remaining question is not whether cells need NAD+. They do. The unresolved issue is what supplying a particular preparation changes in people, for how long, and with what risks. That deserves a slower reading than a single laboratory value.